{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:47:53Z","timestamp":1790066873469,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40268-018-0236-x","type":"journal-article","created":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T08:48:24Z","timestamp":1527756504000},"page":"149-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers"],"prefix":"10.1007","volume":"18","author":[{"given":"Marie","family":"Cullberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Arfvidsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Malmgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"W\u00e4hlby Hamr\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Wray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"issue":"3","key":"236_CR1","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1183\/09031936.00186109","volume":"35","author":"Y Gernez","year":"2010","unstructured":"Gernez Y, Tirouvanziam R, Chanez P. Neutrophils in chronic inflammatory airway diseases: can we target them and how? Eur Respir J. 2010;35(3):467\u20139.","journal-title":"Eur Respir J"},{"issue":"1","key":"236_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/MCP.0000000000000120","volume":"21","author":"P Nair","year":"2015","unstructured":"Nair P, Aziz-Ur-Rehman A, Radford K. Therapeutic implications of \u2018neutrophilic asthma\u2019. Curr Opin Pulm Med. 2015;21(1):33\u20138.","journal-title":"Curr Opin Pulm Med."},{"issue":"2","key":"236_CR3","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/jpet.114.221358","volume":"353","author":"D Nicholls","year":"2015","unstructured":"Nicholls D, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, K\u00e4rrman M\u00e5rdh C. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015;353(2):340\u201350.","journal-title":"J Pharmacol Exp Ther"},{"key":"236_CR4","unstructured":"Gardiner P, Ekdahl A, Palmgren A-P, Cullberg M, Larsson B. The mechanisms and routes of clearance of the CXCR2 antagonist AZD5069 in human. American Association of Pharmaceutical Scientists (AAPS); San Antonio, Texas, USA. 2013."},{"issue":"Supplement 55","key":"236_CR5","first-page":"3984","volume":"38","author":"H Wray","year":"2011","unstructured":"Wray H, Sparrow A. Safety and tolerability of single doses of AZD5069 in healthy volunteers. Eur Respir J. 2011;38(Supplement 55):3984.","journal-title":"Eur Respir J"},{"issue":"1","key":"236_CR6","first-page":"78","volume":"14","author":"H Wray","year":"2012","unstructured":"Wray H, Wilbraham D. Safety and tolerability of AZD5069 in healthy smokers following multiple ascending doses. Int J Immunorehab. 2012;14(1):78.","journal-title":"Int J Immunorehab."},{"issue":"Supplement 56","key":"236_CR7","first-page":"P4842","volume":"40","author":"U Lorch","year":"2012","unstructured":"Lorch U, Negi H, Tabata H, Wray H, Cullberg M, Larsson B. The safety, tolerability and pharmacokinetics of AZD5069, a novel CXCR2 antagonist, in healthy Japanese volunteers. Eur Respir J. 2012;40(Supplement 56):P4842.","journal-title":"Eur Respir J"},{"issue":"Supplement 56","key":"236_CR8","first-page":"P2149","volume":"40","author":"T Mant","year":"2012","unstructured":"Mant T, Wray H, Cullberg M, Larsson B. The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers. Eur Respir J. 2012;40(Supplement 56):P2149.","journal-title":"Eur Respir J"},{"issue":"6","key":"236_CR9","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/bcp.12724","volume":"80","author":"S Jurcevic","year":"2015","unstructured":"Jurcevic S, Humfrey C, Uddin M, Warrington S, Larsson B, Keen C. The effect of a selective CXCR2 antagonist (AZD5069) on human blood neutrophil count and innate immune functions. Br J Clin Pharmacol. 2015;80(6):1324\u201336.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"236_CR10","first-page":"78","volume":"14","author":"H Wray","year":"2012","unstructured":"Wray H, Mant T. Effects of food and age on pharmacokinetics, safety and tolerability of single doses of AZD5069. Int J Immunorehab 2012;14(1):78.","journal-title":"Int J Immunorehab"},{"issue":"Supplement 58","key":"236_CR11","first-page":"P961","volume":"44","author":"M Cullberg","year":"2014","unstructured":"Cullberg M. Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist. Eur Respir J. 2014;44(Supplement 58):P961.","journal-title":"Eur Respir J"},{"issue":"4","key":"236_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1183\/13993003.00148-2015","volume":"46","author":"A Soyza De","year":"2015","unstructured":"De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J. 2015;46(4):1021\u201332.","journal-title":"Eur Respir J"},{"key":"236_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","volume":"31","author":"A Kirsten","year":"2015","unstructured":"Kirsten A, Forster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharmacol Ther. 2015;31:36\u201341.","journal-title":"Pulm Pharmacol Ther"},{"issue":"10","key":"236_CR14","first-page":"797","volume":"4","author":"P O\u2019Byrne","year":"2016","unstructured":"O\u2019Byrne P, Metev H, Puu M, Richter K, Keen C, Uddin MK, Larsson B, Cullberg M, Nair P. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma receiving ICS\/LABA therapy: a phase 2b randomised trial Lancet. Respir Med. 2016;4(10):797\u2013806.","journal-title":"Respir Med"},{"key":"236_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pupt.2017.05.012","volume":"45","author":"H Watz","year":"2017","unstructured":"Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F, Groth E, Larsson B, Bottcher G, Malmgren A, Kraan M, Rabe KF. Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. Pulm Pharmacol Ther. 2017;45:121\u20133.","journal-title":"Pulm Pharmacol Ther"},{"key":"236_CR16","doi-asserted-by":"crossref","unstructured":"Hong D, Falchook G, Cook CE, Harb W, Lyne P, McCoon P, Mehta M, Mitchell P, Mugundum GM, Scott M, Wang JS. A phase 1b study (SCORES) assessing safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of durvalumab combined with AZD9150 or AZD5069 in patients with advanced solid malignancies and SCCHN. Ann Oncol. 2016;27(supplement 6):1049PD.","DOI":"10.1093\/annonc\/mdw378.04"},{"key":"236_CR17","unstructured":"US Dept of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies. 2002."},{"issue":"3","key":"236_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.18773\/austprescr.2013.037","volume":"36","author":"C Lucas","year":"2013","unstructured":"Lucas C, Martin J. Smoking and drug interactions. Aust Prescrib. 2013;36(3):102\u20134.","journal-title":"Aust Prescrib."},{"key":"236_CR19","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Guidance for industry: drug interaction studies\u2014study design, data analysis, and implications for dosing and labeling recommendations. 2012."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-018-0236-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-018-0236-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T21:47:07Z","timestamp":1559252827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-018-0236-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["236"],"URL":"https:\/\/doi.org\/10.1007\/s40268-018-0236-x","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,31]]},"assertion":[{"value":"31 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All studies were sponsored and funded by AstraZeneca. David Candlish, of InScience Communications, Tattenhall, UK, provided editorial and medical writing assistance, which was funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are full-time permanent employees of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}